Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
J. Clin. Invest. 111:9 doi:10.1172/JCI17500
[Go to this article.]
Options: View larger image (or click on image)
Medium
Figure 6

Ligand-binding capacity in cultured PASMCs. Ligand binding of 125I-VIP as a function of concentration to membranes of PASMCs cultured from healthy controls (n = 3) (a) and PPH patients (n = 3) (b). Cells (106) were incubated for 60 min at 4°C in the presence or absence of unlabeled VIP (100 nM) with the various radioligand concentrations (0.01–20 nM). TB, total binding; NSB, nonspecific binding; SB, specific binding. (a) The data of controls, where the specific binding is below 0.3 pmol/6 × 106 cells; (b) PPH cells with an average specific binding well above 0.6 pmol/6 × 106cells.